期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肾癌预后模型及其临床应用

原文传递
导出
摘要 肾细胞癌是泌尿生殖系统常见的恶性肿瘤，其患病率占全身恶性肿瘤的3％，占肾肿瘤的85％以上约25％的肾癌病人存在肿瘤转移[1]。肾癌的预后因素包括：解剖水平（肿瘤大小、TNM分期）、临床水平（临床症状、生活质量评分）、组织学水平（Fuhrman分级、组织学亚型）和分子水平。这些预后因素单独应用不是十分准确[2]。因此国外有学者提出可以使用预后分级系统，将。肾癌的风险进行综合评估分级斤且判断生仔率，用以指导临床治疗及制定随访策略。
作者 谢波涛（综述） 刘孝东 龙江（审校）
机构地区 昆明医学院第一附属医院泌尿外科
出处 《国际泌尿系统杂志》 2011年第6期782-786,共5页 International Journal of Urology and Nephrology
关键词 肾肿瘤 预后 疾病模型 动物
分类号 R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1Brian R, Lane, MichaelW, et al. Predicting outcomes in renal cell carcinoma. Curr Opin Urol, 2005, 15:289-297.
  • 2Alessandro Volpe, Jean Jacques Patard. Prognostic tactors in renal cell carcinoma. World J Urol, 2010, 28:319-327.
  • 3Antonio Galfano, Giacomo Novara, et al. Mathematical Models for Prognostic Prediction in Patients with Renal Cell Carcinoma . Urol lnt, 2008.80:113 - 123.
  • 4Zheng Li..Jaju Lv, et al. Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: A 15 -year single center experience . lnt J Urol, 2009, 16:268-273.
  • 5Luca Cindolo,Jean -Jacques Patard, et al. Comparison of Predictive Accuracy of Four Prognostic Models for Nonmetastatic Renal Cell Carcinoma after Nephrectomy . Cancer, 2005, 104 (7) : 1362 - 1371.
  • 6Vincenzo Ficarra, Giacomo Novara, etal. The Stage, Size, Grade and Necrosis'score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer - specific survival in patients with clear cell renal cell carcinoma . BJU Int, 2009, 103(2) :165 - 170.
  • 7Tobias Klatte, John S. Lam, et al. Surveillance for renal cell carcinoma: Why and how.9 When and how often ? Urol Oncol, 2008, 26 (5) :550 -554.
  • 8John S, Lam, Oleg Shuarts, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nom ogram and risk group stratificaation system . J Urol, 2005, 174:466 - 472.
  • 9Yasuhisa Fujii, Kazutaka Saito, et al. External Validation of the Mayo Clinic Cancer Speeific Survival Score in a Japanese Series of Clear Cell Renal Cell Carcinoma. J Urol, 2008, 180: 1290- 1296.
  • 10R. Houston Thompson, Bradley C. l.eibovich, et al. Dynamic Outcome Prediction in Patients With Clear Cell Renal Cell Carcinoma Treated With Radical Nephreetomy : The D - SSIGN Score. J Urol, 2007. 177(2) : 477 -480.

二级参考文献51

  • 1IGARASHI H,ESUMI M,ISHIDA H,et al.Endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma[J].Cancer,2002,95:47-53.
  • 2RINI BI,CAMPBELL SC,ESCUDIER B.Renal cellcarcinoma[J].Lancet,2009,373:1119-1132.
  • 3SUN L.LIANG C,SHIRAZIAN S,et al.Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl] -2,4-dimethyl-1Hpyrrole-3-carboxylic acid(2-diethylaminoethyl)amide,a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase[J].J Med Chem,2003,46:1116-1119.
  • 4O'FARELL AM,ABRAMS TJ,YUEN HA,et al.SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo[J].Blood,2003,101:3597-3605.
  • 5MENDEL DB,LAIRD AD,XIN X,et al.,In vivo antitumor activity of SU11248,a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors:determination of a pharmacokinetic/ pharmacodynamic relationship[J].Clin Cancer Res,2003,9:327-337.
  • 6MOTZER RJ,DROR MICHAELSON M,REDMAN BG,et al.Activity of SU11248,a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor,in patients with metastatic renal cell carcinoma[J].J Clin Oncol,2006,24:16-24.
  • 7MOTZER RJ,RINI BI,BUKOWSKI RM,et al.Sunitinib in patients with metastatic renal cell carcinoma[J].JAMA,2006,295:2516-2524.
  • 8MOTZER RJ,HUTSON TE,TOMCZAK P,et al.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[J].J Clin Oncol,2009,27:3584-3590.
  • 9DOWNWARD J.Targeting RAS signalling pathways in cancer therapy[J].Nature Rev Cancer,2003,3:11-322.
  • 10ESCUDIER B,EISEN T,STADLER WM,et al.Sorafenib for treatment of renal cell carcinoma:Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial[J].J Clin Oncol,2009,27:3312-3318.

共引文献9

国际泌尿系统杂志
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部